Natural products company Hypha Discovery has signed a deal with Domainex to develop novel oncology drugs. Hypha has identified a pipeline of natural products with activity against tumor cell lines, including the HD148 chemical series inspired by compounds from a tropical mushroom. Domainex will use its drug development platform and medicinal chemistry expertise to optimize the HD148 series and deliver an advanced lead molecule and clinical candidate. Both companies look forward to the collaboration advancing Hypha's oncology programs.